Literature DB >> 23290822

The molecular changes driving the carcinogenesis in Barrett's esophagus: which came first, the chicken or the egg?

A Russo1, G Bronte, D Cabibi, V Bazan, G Cicero, A Bertani, S Rizzo, E Fiorentino.   

Abstract

Esophageal adenocarcinoma originates from columnar metaplastic epithelium of the distal esophagus. Various steps for this carcinogenetic process are known. Before the onset of high-grade dysplasia and adenocarcinoma, endoscopic surveillance is possible. However, because of the high cost of long-term surveillance, predictive factors for cancer are being evaluated to identify subjects with metaplasia who have a higher risk of developing malignancy. Molecular changes seem suitable for this purpose, but could require a high resource expenditure. While trying to identify the best predictive factors for cancer risk, molecular changes and differences in miRNA expression profile between the various steps leading to cancer could help to clarify Barrett's carcinogenesis. In this attempt to find a molecular explanation for the onset of esophageal adenocarcinoma, it is still difficult to understand whether the molecular changes are causes or effects of the neoplastic phenotypic modifications.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23290822     DOI: 10.1016/j.critrevonc.2012.12.001

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  3 in total

Review 1.  [Barrett's esophagus].

Authors:  J Labenz
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

Review 2.  The epidemiology, diagnosis, and treatment of Barrett's carcinoma.

Authors:  Joachim Labenz; Herbert Koop; Andrea Tannapfel; Ralf Kiesslich; Arnulf H Hölscher
Journal:  Dtsch Arztebl Int       Date:  2015-03-27       Impact factor: 5.594

3.  GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

Authors:  Romana Illig; Eckhard Klieser; Tobias Kiesslich; Daniel Neureiter
Journal:  Gastroenterol Res Pract       Date:  2013-03-20       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.